CN113993507B - 包含伊立替康游离碱的用于口服施用的药物组合物 - Google Patents

包含伊立替康游离碱的用于口服施用的药物组合物 Download PDF

Info

Publication number
CN113993507B
CN113993507B CN202080044224.6A CN202080044224A CN113993507B CN 113993507 B CN113993507 B CN 113993507B CN 202080044224 A CN202080044224 A CN 202080044224A CN 113993507 B CN113993507 B CN 113993507B
Authority
CN
China
Prior art keywords
pharmaceutical composition
sorbitan
weight
polyoxylglyceride
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080044224.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113993507A (zh
Inventor
张准熙
李仁铉
孙旼希
朴惠珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dae Hwa Pharma Co ltd
Original Assignee
Dae Hwa Pharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Hwa Pharma Co ltd filed Critical Dae Hwa Pharma Co ltd
Publication of CN113993507A publication Critical patent/CN113993507A/zh
Application granted granted Critical
Publication of CN113993507B publication Critical patent/CN113993507B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080044224.6A 2019-06-20 2020-06-12 包含伊立替康游离碱的用于口服施用的药物组合物 Active CN113993507B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0073344 2019-06-20
KR1020190073344A KR102185475B1 (ko) 2019-06-20 2019-06-20 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
PCT/KR2020/007628 WO2020256349A1 (ko) 2019-06-20 2020-06-12 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Publications (2)

Publication Number Publication Date
CN113993507A CN113993507A (zh) 2022-01-28
CN113993507B true CN113993507B (zh) 2023-08-01

Family

ID=73792076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044224.6A Active CN113993507B (zh) 2019-06-20 2020-06-12 包含伊立替康游离碱的用于口服施用的药物组合物

Country Status (7)

Country Link
US (1) US20220313684A1 (pt)
EP (1) EP3977987A4 (pt)
JP (1) JP7492977B2 (pt)
KR (1) KR102185475B1 (pt)
CN (1) CN113993507B (pt)
BR (1) BR112021025668A2 (pt)
WO (1) WO2020256349A1 (pt)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960729A (zh) * 2004-06-01 2007-05-09 泰尔茂株式会社 伊立替康制剂
CN103830182A (zh) * 2014-03-11 2014-06-04 江苏奥赛康药业股份有限公司 一种长循环伊立替康脂质体组合物及其制备方法
CN107949375A (zh) * 2015-06-30 2018-04-20 韩美药品株式会社 含有伊立替康的口服固体制剂及其制备方法
CN108578368A (zh) * 2018-04-13 2018-09-28 华东师范大学 一种伊立替康-胆固醇琥珀酸单脂离子对及脂质体和制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
CN1774249A (zh) * 2003-04-28 2006-05-17 法玛西雅厄普约翰有限责任公司 伊立替康在治疗耐受性乳腺癌中的应用
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CA2928772A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
US10143657B2 (en) * 2014-01-17 2018-12-04 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
KR101542364B1 (ko) 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
WO2017018635A1 (ko) * 2015-07-30 2017-02-02 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR101612257B1 (ko) 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960729A (zh) * 2004-06-01 2007-05-09 泰尔茂株式会社 伊立替康制剂
CN103830182A (zh) * 2014-03-11 2014-06-04 江苏奥赛康药业股份有限公司 一种长循环伊立替康脂质体组合物及其制备方法
CN107949375A (zh) * 2015-06-30 2018-04-20 韩美药品株式会社 含有伊立替康的口服固体制剂及其制备方法
CN108578368A (zh) * 2018-04-13 2018-09-28 华东师范大学 一种伊立替康-胆固醇琥珀酸单脂离子对及脂质体和制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
7-乙基-10-羟基喜树碱衍生物药理学性质研究进展;吴婵等;《国际药学研究杂志》;第42卷(第3期);310-315 *
Efficient co-delivery of immiscible hydrophilic/ hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer;Zhang et al.;《International Journal of Nanomedicine》;第12卷;2871-2886 *

Also Published As

Publication number Publication date
EP3977987A1 (en) 2022-04-06
EP3977987A4 (en) 2023-06-21
BR112021025668A2 (pt) 2022-02-08
WO2020256349A1 (ko) 2020-12-24
JP2022538002A (ja) 2022-08-31
CN113993507A (zh) 2022-01-28
KR102185475B1 (ko) 2020-12-02
US20220313684A1 (en) 2022-10-06
JP7492977B2 (ja) 2024-05-30

Similar Documents

Publication Publication Date Title
EP1940366B9 (en) Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
Bartlett et al. Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine
JP2006501134A (ja) 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物
EP3355881B1 (en) Oral taxane compositions and methods
WO2003045357A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
SK279845B6 (sk) Farmaceutický prostriedok, spôsob jeho prípravy a
MXPA02003904A (es) Formulaciones orales para compuestos antitumorales.
Khan et al. Parenteral sustained release lipid phase-transition system of ziprasidone: Fabrication and evaluation for schizophrenia therapy
KR101739820B1 (ko) 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
CN113993507B (zh) 包含伊立替康游离碱的用于口服施用的药物组合物
CN111511349B (zh) 包含伊立替康或其药剂学上可接受的盐的用于口服给药的药剂学组合物
ZA200604757B (en) Pharmaceutical formulations of camptothecins and process for making same
US20210137917A1 (en) Pharmaceutical composition of nintedanib esylate
US20070020333A1 (en) Controlled release of hypnotic agents
EP1530459B1 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
ZA200405992B (en) Oral pharmaceutical composition for soft capsule containing vinorelbine and method of treatment
EP4321152A1 (en) Sustained-release lipid pre-concentrate
US20060094692A1 (en) Pharmaceutical formulations of camptothecins and process for making same
CN116350619A (zh) 一种口服紫杉烷类药物组合物
WO2011000811A2 (en) Organic compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant